Lexicon Pharmaceuticals Q4 net loss narrows on lower R&D spend

Reuters03-05

Lexicon Pharmaceuticals Q4 net loss narrows on lower R&D spend

Overview

Biopharmaceutical firm's Q4 revenue decreased significantly compared to last year
Net loss for Q4 narrowed to $15.5 mln from $33.8 mln last year
Company strengthened financial position with over $100 mln in additional cash

Outlook

Lexicon expects SONATA-HCM study enrollment to complete by mid-2026
Company plans NDA resubmission for ZYNQUISTA in 2026
Lexicon supports Viatris in regulatory filings for sotagliflozin in 2026

Result Drivers

EXPENSE REDUCTION - Decreased R&D and SG&A expenses contributed to a narrowed net loss for Q4 2025

Company press release: ID:nGNX5DRRX6

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q4 Product Revenue		$1.06 mln
Q4 EPS		-$0.04
Q4 Net Income		-$15.53 mln
Q4 Basic EPS		-$0.04
Q4 Operating Expenses		$20.27 mln
Q4 Operating Income		-$14.78 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Lexicon Pharmaceuticals Inc is $3.05, about 87.1% above its March 4 closing price of $1.63

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2617417015?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-05 20:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2617417015","market":"us","top_or_hot":-1,"title":"Lexicon Pharmaceuticals Q4 net loss narrows on lower R&D spend","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Lexicon Pharmaceuticals Q4 net loss narrows on lower R&amp;D spend</title></head><body><p><span>Overview</span></p><ul><li><p>Biopharmaceutical firm's Q4 revenue decreased significantly compared to last year</p></li><li><p>Net loss for Q4 narrowed to $15.5 mln from $33.8 mln last year</p></li><li><p>Company strengthened financial position with over $100 mln in additional cash</p></li></ul><p><span>Outlook</span></p><ul><li><p>Lexicon expects SONATA-HCM study enrollment to complete by mid-2026</p></li><li><p>Company plans NDA resubmission for ZYNQUISTA in 2026</p></li><li><p>Lexicon supports Viatris in regulatory filings for sotagliflozin in 2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>EXPENSE REDUCTION - Decreased R&amp;D and SG&amp;A expenses contributed to a narrowed net loss for Q4 2025</p></li></ul><p>Company press release: <span>ID:nGNX5DRRX6</span></p><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 Product Revenue</p></td><td></td><td><p>$1.06 mln</p></td><td></td></tr><tr><td><p>Q4 EPS</p></td><td></td><td><p>-$0.04</p></td><td></td></tr><tr><td><p>Q4 Net Income</p></td><td></td><td><p>-$15.53 mln</p></td><td></td></tr><tr><td><p>Q4 Basic EPS</p></td><td></td><td><p>-$0.04</p></td><td></td></tr><tr><td><p>Q4 Operating Expenses</p></td><td></td><td><p>$20.27 mln</p></td><td></td></tr><tr><td><p>Q4 Operating Income</p></td><td></td><td><p>-$14.78 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 3 \"strong buy\" or \"buy\", 2 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Lexicon Pharmaceuticals Inc is $3.05, about 87.1% above its March 4 closing price of $1.63</p></li></ul><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lexicon Pharmaceuticals Q4 net loss narrows on lower R&D spend</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLexicon Pharmaceuticals Q4 net loss narrows on lower R&D spend\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-05 20:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Lexicon Pharmaceuticals Q4 net loss narrows on lower R&amp;D spend</title></head><body><p><span>Overview</span></p><ul><li><p>Biopharmaceutical firm's Q4 revenue decreased significantly compared to last year</p></li><li><p>Net loss for Q4 narrowed to $15.5 mln from $33.8 mln last year</p></li><li><p>Company strengthened financial position with over $100 mln in additional cash</p></li></ul><p><span>Outlook</span></p><ul><li><p>Lexicon expects SONATA-HCM study enrollment to complete by mid-2026</p></li><li><p>Company plans NDA resubmission for ZYNQUISTA in 2026</p></li><li><p>Lexicon supports Viatris in regulatory filings for sotagliflozin in 2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>EXPENSE REDUCTION - Decreased R&amp;D and SG&amp;A expenses contributed to a narrowed net loss for Q4 2025</p></li></ul><p>Company press release: <span>ID:nGNX5DRRX6</span></p><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 Product Revenue</p></td><td></td><td><p>$1.06 mln</p></td><td></td></tr><tr><td><p>Q4 EPS</p></td><td></td><td><p>-$0.04</p></td><td></td></tr><tr><td><p>Q4 Net Income</p></td><td></td><td><p>-$15.53 mln</p></td><td></td></tr><tr><td><p>Q4 Basic EPS</p></td><td></td><td><p>-$0.04</p></td><td></td></tr><tr><td><p>Q4 Operating Expenses</p></td><td></td><td><p>$20.27 mln</p></td><td></td></tr><tr><td><p>Q4 Operating Income</p></td><td></td><td><p>-$14.78 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 3 \"strong buy\" or \"buy\", 2 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Lexicon Pharmaceuticals Inc is $3.05, about 87.1% above its March 4 closing price of $1.63</p></li></ul><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LXRX","symbol_name":"莱斯康制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nL1N3ZT0KH:1","article_id":"2617417015","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2617417015","pubTimestamp":1772712435,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Lexicon Pharmaceuticals Q4 net loss narrows on lower R&D spendOverviewBiopharmaceutical firm's Q4 revenue decreased significantly compared to last yearNet loss for Q4 narrowed to $15.5 mln from $33.8 ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LXRX":"莱斯康制药","BK4583":"猴痘概念","BK4588":"碎股","BK4585":"ETF&股票定投概念","LU1839511570.USD":"WELLS FARGO GLOBAL FACTOR ENHANCED EQUITY \"I\" (USD) ACC","BK4139":"生物科技","LU2087621335.USD":"ALLSPRING GLOBAL FACTOR ENHANCED EQUITY \"A\" (USD) ACC","BK4007":"制药","VTRS":"Viatris Inc."},"translate_title":"Lexicon Pharmaceuticals第四季度净亏损因研发支出减少而收窄","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VTRS":0.9,"LXRX":0.9},"content_text":"Lexicon Pharmaceuticals Q4 net loss narrows on lower R&D spendOverviewBiopharmaceutical firm's Q4 revenue decreased significantly compared to last yearNet loss for Q4 narrowed to $15.5 mln from $33.8 mln last yearCompany strengthened financial position with over $100 mln in additional cashOutlookLexicon expects SONATA-HCM study enrollment to complete by mid-2026Company plans NDA resubmission for ZYNQUISTA in 2026Lexicon supports Viatris in regulatory filings for sotagliflozin in 2026Result DriversEXPENSE REDUCTION - Decreased R&D and SG&A expenses contributed to a narrowed net loss for Q4 2025Company press release: ID:nGNX5DRRX6Key DetailsMetricBeat/MissActualConsensus EstimateQ4 Product Revenue$1.06 mlnQ4 EPS-$0.04Q4 Net Income-$15.53 mlnQ4 Basic EPS-$0.04Q4 Operating Expenses$20.27 mlnQ4 Operating Income-$14.78 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 3 \"strong buy\" or \"buy\", 2 \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the biotechnology & medical research peer group is \"buy\"Wall Street's median 12-month price target for Lexicon Pharmaceuticals Inc is $3.05, about 87.1% above its March 4 closing price of $1.63For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2617417015","isCrawlerRequest":true}